<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDF68AF7-667A-4893-97C9-11432E06D8DA"><gtr:id>DDF68AF7-667A-4893-97C9-11432E06D8DA</gtr:id><gtr:name>Planet Biotechnology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/88077807-2572-4B6D-8467-0822C6A212BD"><gtr:id>88077807-2572-4B6D-8467-0822C6A212BD</gtr:id><gtr:name>NHS Blood and Transplant (NHSBT)</gtr:name><gtr:address><gtr:line1>Oak House
Reeds Crescent</gtr:line1><gtr:city>Watford</gtr:city><gtr:postCode>WD24 4QN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0F9A74A9-4595-4E3C-8DC6-3A5B4D904568"><gtr:id>0F9A74A9-4595-4E3C-8DC6-3A5B4D904568</gtr:id><gtr:name>National University of Colombia</gtr:name><gtr:address><gtr:line1>Carrera 45 No 26-85</gtr:line1><gtr:line2>Edificio Uriel Gutierrez</gtr:line2><gtr:line4>Bogota</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Colombia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E6DF5D67-D7D6-4891-9B77-959BE9D17DAC"><gtr:id>E6DF5D67-D7D6-4891-9B77-959BE9D17DAC</gtr:id><gtr:name>The Walter and Eliza Hall Institute of Medical Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F6B629B3-C879-405F-A7CD-88B6716CCAB2"><gtr:id>F6B629B3-C879-405F-A7CD-88B6716CCAB2</gtr:id><gtr:name>Burnet Institute</gtr:name><gtr:address><gtr:line1>GPO Box 2284</gtr:line1><gtr:postCode>3001</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:department>Wellcome Trust Genome Campus</gtr:department><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDF68AF7-667A-4893-97C9-11432E06D8DA"><gtr:id>DDF68AF7-667A-4893-97C9-11432E06D8DA</gtr:id><gtr:name>Planet Biotechnology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/88077807-2572-4B6D-8467-0822C6A212BD"><gtr:id>88077807-2572-4B6D-8467-0822C6A212BD</gtr:id><gtr:name>NHS Blood and Transplant (NHSBT)</gtr:name><gtr:address><gtr:line1>Oak House
Reeds Crescent</gtr:line1><gtr:city>Watford</gtr:city><gtr:postCode>WD24 4QN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0F9A74A9-4595-4E3C-8DC6-3A5B4D904568"><gtr:id>0F9A74A9-4595-4E3C-8DC6-3A5B4D904568</gtr:id><gtr:name>National University of Colombia</gtr:name><gtr:address><gtr:line1>Carrera 45 No 26-85</gtr:line1><gtr:line2>Edificio Uriel Gutierrez</gtr:line2><gtr:line4>Bogota</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Colombia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E6DF5D67-D7D6-4891-9B77-959BE9D17DAC"><gtr:id>E6DF5D67-D7D6-4891-9B77-959BE9D17DAC</gtr:id><gtr:name>The Walter and Eliza Hall Institute of Medical Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F6B629B3-C879-405F-A7CD-88B6716CCAB2"><gtr:id>F6B629B3-C879-405F-A7CD-88B6716CCAB2</gtr:id><gtr:name>Burnet Institute</gtr:name><gtr:address><gtr:line1>GPO Box 2284</gtr:line1><gtr:postCode>3001</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7C42544C-E9A7-48DF-B706-479A3C42E9B2"><gtr:id>7C42544C-E9A7-48DF-B706-479A3C42E9B2</gtr:id><gtr:firstName>Julian</gtr:firstName><gtr:surname>Rayner</gtr:surname><gtr:orcidId>0000-0002-9835-1014</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DC65FFF0-822E-425A-9169-81B65A3E428E"><gtr:id>DC65FFF0-822E-425A-9169-81B65A3E428E</gtr:id><gtr:firstName>Gavin</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Wright</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ002283%2F1"><gtr:id>B18CA629-BA99-4E1A-9CA4-0AE5D0A88D11</gtr:id><gtr:title>A comprehensive survey of protein-protein interactions between Plasmodium falciparum merozoites and human receptors</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J002283/1</gtr:grantReference><gtr:abstractText>Malaria is one of the most common infectious diseases in the world, with more than 300 million cases of malaria each year, leading to more than 1 million deaths, primarily in children under the age of five in Africa. Malaria is caused by single-celled Plasmodium parasites and one species is particularly deadly - Plasmodium falciparum - which is responsible for almost all malaria deaths. Plasmodium parasites have a complex life cycle, but all the symptoms of malaria are caused when they invade human red blood cells, also known as erythrocytes. The parasite uses the erythrocyte as a source of food, multiplies inside it, and, after 48 hours, breaks open the erythrocyte to release multiple new parasites. This cycle of invasion, multiplication and re-invasion results in high numbers of parasites in the blood stream.

Because Plasmodium parasites spend the majority of their life cycle inside human cells, they are difficult to target with vaccines, and there is currently no licensed vaccine for malaria. However, the process of erythrocyte invasion is one of the few stages of the parasite's life cycle when they are exposed to the host immune system, and is therefore a potential target for vaccine-induced invasion-blocking antibodies or drug development. For vaccines or drugs to be developed, it is critical that we understand which proteins on the parasite surface are binding directly to erythrocytes and the identity of the erythrocyte proteins that they are binding to. By first identifying these parasite-erythrocyte interactions, it may be possible to develop novel therapeutics that prevent invasion and hence cure or prevent malaria. Research over the last two decades has led to the identification of numerous P. falciparum proteins that may be involved in erythrocyte invasion, but only in very cases do we know which erythrocyte proteins they bind to. This is in large part because of the technical challenges involved: protein-protein interactions between the surface of cells are often very short-lived (lasting only a few seconds) and so are very difficult to detect using standard experimental approaches.

At the Wellcome Trust Sanger Institute we have recently developed a new approach to detect short-lived protein-protein interactions. Called AVEXIS (Avidity based Extracellular Interaction Screen), it uses libraries of proteins, expressed and purified in the lab, to detect novel interactions. Over the last two years we have started to apply this to the process of P. falciparum erythrocyte invasion and have created small pilot libraries of erythrocyte and P. falciparum proteins to screen for interactions. This preliminary work has identified two new parasite-erythrocyte interactions, one of which appears to play a very important role in erythrocyte invasion. However, this initial screen was limited in scope and we still do not have binding partners for the majority of P. falciparum proteins. In this research we will expand our libraries of parasite and erythrocyte proteins, and also include other components of the host blood which P. falciparum parasites may be interacting with, such as sugar structures that are present on cell surfaces. After screening the parasite and blood component libraries for interactions in an all vs. all manner, we will test whether any newly discovered interactions have roles in erythrocyte invasion using P. falciparum parasites that can be cultured in the lab. This research will build up the first systematic map of interactions between P. falciparum proteins and human blood cell components, and will identify protein-protein interactions that are of particular interest for vaccine or drug development. We will also deposit the DNA constructs that are used to create our recombinant protein libraries in not-for-profit reagent resource collections, where they can be freely accessed by other researchers and thereby empower malaria research in many labs across the globe.</gtr:abstractText><gtr:technicalSummary>Plasmodium falciparum parasites cause more than a million deaths from malaria each year. All the symptoms and pathology of malaria are caused by the blood stages of P. falciparum development, which are initiated when merozoites invade human erythrocytes. Erythrocyte invasion is potentially an attractive vaccine target because it is essential to parasite survival and the extracellular ligands that catalyse it are exposed on the parasite surface. Although many candidate P. falciparum ligands have been identified, in very few cases are their host receptors known, in part because cell surface protein-protein interactions are often of very low affinity, making them difficult to detect using standard approaches.

We will address this important gap in our understanding using AVEXIS, a protein-protein interaction technology developed at the Sanger Institute specifically to detect low affinity interactions. A pilot screen has already identified two novel P. falciparum-erythrocyte interactions, including one that plays a critical role in invasion. To expand these studies, we will:
1) Construct a comprehensive library of recombinant P. falciparum merozoite proteins
2) Screen the library against human erythrocytes to identify erythrocyte binding proteins
3) Identify carbohydrate receptors for merozoite ligands by screening glycan arrays
4) Identify protein receptors by using AVEXIS to screen libraries of human erythrocyte receptors or other soluble blood components
5) Validate the function of identified interactions using in vitro cultured P. falciparum parasites.
This approach will generate the first biochemically validated map of interactions between P. falciparum merozoite proteins and human blood cell components, and will identify protein-protein interactions that are of particular interest for vaccine or drug development. All expression constructs will be deposited in not-for-profit reagent resource collections to empower research in other labs.</gtr:technicalSummary><gtr:potentialImpactText>Malaria is responsible for around 1 million deaths annually and the emergence and spread of drug-resistant strains is now a major global health concern. The economic cost of this disease is significant, estimated to represent up to 1.3% of GDP in countries with high transmission rates. The overarching, long-term goal of this research is to make a contribution towards an effective and cost-effective preventative treatment for malaria. The development of an effective vaccine for this disease would have a huge impact on global health and is a top priority for many public and privately led funding initiatives.

Scientific researchers working in the immediate subject area will be clear beneficiaries of this work, as outlined in the 'Academic Beneficiaries' section. In the context of translational impact, this research will be of particular benefit to researchers working within the global malaria vaccine initiatives both in the public and private sector. Merozoite proteins are regarded as excellent vaccine candidates. Should a single or multi-component blood-stage vaccine be an effective treatment for malaria, it is highly likely that one or more of the proteins within our recombinant merozoite protein resource will be a component of such a vaccine. Given our success in high level expression of functional proteins, the experience of expressing antigens in this project will be of clear utility to other vaccine projects focusing on the same targets. Furthermore, we have already shown that the combination of biochemical and in vitro approaches can make important functional insights into the role of merozoite proteins. The results of this work will therefore also help to rationalise antigen targets on the basis of function, and thereby provide a rational focus for vaccine development.

The ultimate aim of this research will be to identify candidate antigens that would lead towards a highly effective blood-stage vaccine, whether driven by ourselves or others. When this is achieved, the primary beneficiaries of this research would be the many billions of people living in malaria-endemic regions. A successful vaccine against malaria would therefore have a huge global health impact. This proposal is aimed at making a contribution towards this goal by expressing and determining the function of P. falciparum merozoite proteins. The timescale for any identified target/s to be used in a licensed vaccine is likely to be 10 to 20 years. The economic impact of an effective anti-malarial vaccine would be enormous, relieving a huge healthcare, economic and social burden from some of the poorest countries in the world, and also enabling non-native people travelling to and working in these countries to be effectively protected.

More broadly, the approach of producing recombinant protein libraries representing the surface repertoire of differentiated cell types to identify the receptors for pathogens is one that could be applied to other stages of the Plasmodium lifecycle, which also present important intervention targets. One important example is transmission-blocking vaccines, which have been identified as a high priority as part of the move towards malaria elimination. The same approaches could also be applied to other pathogens of global public health importance, including other parasites as well as viruses and bacteria.

Researchers employed on this grant would gain important skills necessary for producing and elucidating the function of P. falciparum merozoite proteins, which could play an important role in their own career development. These would include the expression systems used to produce the proteins and also the skills to culture and perform functional assays on P. falciparum parasites. The wider dissemination of these skills may lead to important insights in the function of merozoite proteins in other research environments.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>359272</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>'Parasite' has been created by artist Deborah Robinson working in close collaboration with Wellcome Trust Sanger Institute malaria researchers Julian Rayner and Oliver Billker. During a residency at the Sanger Institute, Deborah explored how genomics is being used to understand the biology of the parasite that causes malaria and how this may be used to establish new ways of preventing or treating the disease. 

For this exhibition Deborah has used sections of archival films which she found within the Wellcome Collection and Imperial War Museum Library and which depict the 'mass eradication' campaigns which characterised attempts to control the disease in the last century. She deploys software, developed with digital and sound artist David Strang, to corrode sections of this archival documentary footage and reminding us of the cyclical and recurrent nature of this deadly disease. 

This project was funded by Arts Council England and was displayed at the Ruskin Gallery in the Cambridge School of Art at Anglia Ruskin University until 18 July 2013.</gtr:description><gtr:id>33FAFAD9-D637-4C9C-971D-5CA2D78FABF9</gtr:id><gtr:impact>Talks about Parasite have taken place at: Inspace (Bio informatics gallery), Edinburgh University; Tent Gallery, Edinburgh University; St John's College, Cambridge; Exeter University. In 2013 Parasite was selected for inclusion in the Shanghai International Science and Art exhibition where it won an award for excellence in Science and Art. 

Solo exhibitions featuring Parasite have taken place at the Ruskin Gallery, Cambridge, July 2013, ICIA, University of Bath, March 2014. Heidelberg Castle, Germany, May 2014 (sponsored by The European Virtual Institute of Malaria Research and EVIMalaR) and at an international exhibition in Shanghai. It is now installed at the Wellcome Genome Campus Conference Centre.</gtr:impact><gtr:outcomeId>54536726dd1632.54507270</gtr:outcomeId><gtr:title>Parasite</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:url>http://www.sanger.ac.uk/about/engagement/art.html</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust</gtr:collaboratingOrganisation><gtr:country>Kenya, Republic of</gtr:country><gtr:department>KEMRI-Wellcome Trust Research Programme</gtr:department><gtr:description>Gathoni Kamuyu - PhD Student</gtr:description><gtr:id>DF45C04B-A108-4F03-ADCE-C5D7706BA527</gtr:id><gtr:impact>Future research directions developed. Publications expected in 2016/17.</gtr:impact><gtr:outcomeId>5460ed41ddc931.62443813-1</gtr:outcomeId><gtr:partnerContribution>Gathoni's work is co-supervised by Faith Osier at KEMRI-Kilifi. This link enables access to invaluable longitudinal cohort data and samples.</gtr:partnerContribution><gtr:piContribution>Gathoni is a graduate student, who is pursuing a PhD under Faith Osier's supervision. I am a co-supervisor on her PhD, and she is visiting my lab for a year, working on proteomic approaches to identify new vaccine targets. The expression system in HEK293E cells is at the core of the validation approaches.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National University of Colombia</gtr:collaboratingOrganisation><gtr:country>Colombia, Republic of</gtr:country><gtr:description>Screening for targets of immunity in Colombia</gtr:description><gtr:id>DF678994-58B8-49EE-80D2-9F91880B8F11</gtr:id><gtr:impact>Successful grant application, reported under relevant section</gtr:impact><gtr:outcomeId>56d5bbd0381f31.20823671-1</gtr:outcomeId><gtr:partnerContribution>Collection of samples, establishing community links and links to local health agencies</gtr:partnerContribution><gtr:piContribution>Using P. falciparum and P. vivax antigen production in HEK293E cells to screen for targets of immunity, and detect asymptomatic infection, in communities on the Pacific Coast of Colombia</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of St Andrews</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine St Andrews</gtr:department><gtr:description>Expression of Plasmodium knowlesi invasion ligands</gtr:description><gtr:id>EB0E6801-4060-47C0-8340-81806DE42EA3</gtr:id><gtr:impact>Some expression trials carried out; followup possible in the future but not a priority for either collaborating lab at this time.</gtr:impact><gtr:outcomeId>GnDecv4DvLQ-1</gtr:outcomeId><gtr:partnerContribution>Providing P. knowlesi invasion ligand sequences</gtr:partnerContribution><gtr:piContribution>Plans underway to express fragments of Plasmodium knowlesi invasion ligands on the HEK293E expression system being used for Plasmodium falciparum expression</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Expression of Plasmodium vivax merozoite proteins</gtr:description><gtr:id>556D1CBB-45F4-4BA5-826A-F32321231CAC</gtr:id><gtr:impact>Library expression now published. Initial immunoepidemiology screen under review in PLoS NTD.</gtr:impact><gtr:outcomeId>ETVvKzVVDYw-1</gtr:outcomeId><gtr:partnerContribution>Provided P. vivax infected patient serum from Cambodia, Papua New Guinea and Solomon Islands for immunoepidemiology studies</gtr:partnerContribution><gtr:piContribution>Expression of a sub-library of Plasmodium vivax merozoite proteins for binding and immunoepidemiology studies</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Blood and Transplant (NHSBT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Testing Plasmodium protein binding to reticulocytes</gtr:description><gtr:id>89A8B6C9-11E3-4801-9E35-96C5FAAA157C</gtr:id><gtr:impact>Initial testing underway</gtr:impact><gtr:outcomeId>pUfQ73SvXNP-1</gtr:outcomeId><gtr:partnerContribution>Differentiating reticulocytes from HSCs and shipping to Sanger for testing</gtr:partnerContribution><gtr:piContribution>Testing binding of Plasmodium proteins to reticulocytes differentiated from HSCs at NHSBT. Initial data equivocal; collaboration may be restarted at a later date.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Burnet Institute</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Centre for Infection</gtr:department><gtr:description>Video microscopy of Plasmodium erythrocyte invasion</gtr:description><gtr:id>1C849B65-671E-48D9-A1FD-E1DC3600E748</gtr:id><gtr:impact>Papers planned for submission 2016/17</gtr:impact><gtr:outcomeId>ff8YUUDadq2-1</gtr:outcomeId><gtr:partnerContribution>Video microscopy based phenotyping of invasion</gtr:partnerContribution><gtr:piContribution>Sharing protein and antibody reagents to test their ability to block invasion in video microscopy based phenotyping assays. Some initial exploratory work carried out at Burnet Institute, but now detailed followup being carried out by co-supervised PhD students at the Cavendish lab, to dissect the molecular steps that protein-ligand interactions catalyse during invasion.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust</gtr:collaboratingOrganisation><gtr:country>Kenya, Republic of</gtr:country><gtr:department>KEMRI-Wellcome Trust Research Programme</gtr:department><gtr:description>Using recombinant proteins to identify new vaccine candidates</gtr:description><gtr:id>5B8CA7E7-B15A-4C90-9582-2770945E2A35</gtr:id><gtr:impact>Co-authored paper led by Kevin Marsh and Faith Osier; reported elsewhere. Other publications in development.</gtr:impact><gtr:outcomeId>546087816bf262.82457362-1</gtr:outcomeId><gtr:partnerContribution>Used the proteins to screen sera samples from longitudinal epidemiological cohorts</gtr:partnerContribution><gtr:piContribution>Provided Plasmodium falciparum recombinant proteins produced from this funding and other sources for use in immunoepidemiology screens, and to generate antibodies for use in inhibition testing.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Walter and Eliza Hall Institute of Medical Research (WEHI)</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Expression of Plasmodium vivax merozoite proteins</gtr:description><gtr:id>95E76737-3DE1-4DE0-B581-AF1A9F488BE0</gtr:id><gtr:impact>Library expression now published. Initial immunoepidemiology screen under review in PLoS NTD.</gtr:impact><gtr:outcomeId>ETVvKzVVDYw-2</gtr:outcomeId><gtr:partnerContribution>Provided P. vivax infected patient serum from Cambodia, Papua New Guinea and Solomon Islands for immunoepidemiology studies</gtr:partnerContribution><gtr:piContribution>Expression of a sub-library of Plasmodium vivax merozoite proteins for binding and immunoepidemiology studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cavendish Laboratory</gtr:department><gtr:description>Video microscopy of Plasmodium erythrocyte invasion</gtr:description><gtr:id>E536416B-FB07-44CA-94C6-097C1B382796</gtr:id><gtr:impact>Papers planned for submission 2016/17</gtr:impact><gtr:outcomeId>ff8YUUDadq2-2</gtr:outcomeId><gtr:partnerContribution>Video microscopy based phenotyping of invasion</gtr:partnerContribution><gtr:piContribution>Sharing protein and antibody reagents to test their ability to block invasion in video microscopy based phenotyping assays. Some initial exploratory work carried out at Burnet Institute, but now detailed followup being carried out by co-supervised PhD students at the Cavendish lab, to dissect the molecular steps that protein-ligand interactions catalyse during invasion.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Planet Biotechnology</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Trialing plant-based expression systems for Plasmodium proteins</gtr:description><gtr:id>0F19EE4E-DCF0-48E5-8F19-6CC78F58BDC0</gtr:id><gtr:impact>Initial expression trials underway</gtr:impact><gtr:outcomeId>rCiGNZ7ddcX-1</gtr:outcomeId><gtr:partnerContribution>Expression trials</gtr:partnerContribution><gtr:piContribution>Providing vectors for expression of Plasmodium proteins in tobacco systems. Trialing expressed proteins in in vitro Plasmodium invasion assays</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard T.H. Chan School of Public Health</gtr:department><gtr:description>Testing Plasmodium vivax vaccine candidates in ex vivo invasion assays</gtr:description><gtr:id>69AEDB9B-3B71-4BF5-B0E1-B07094EC2C21</gtr:id><gtr:impact>First joint publication planned for 2016; first invasion assays for late 2016; joint funding application planned for June 2016.</gtr:impact><gtr:outcomeId>56d6b18fcf0546.86562273-1</gtr:outcomeId><gtr:partnerContribution>Short term ex vivo culture of patient P. vivax isolates.</gtr:partnerContribution><gtr:piContribution>There is no in vitro culture system for Plasmodium vivax, so any vaccine testing will have to take place ex vivo. We have begun to collaborate with Prof. Manoj Duraisingh to carry out such assays at a field site in Goa, India, using antibodies raised against HEK239E expressed vaccine candidates.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Wellcome Trust Drama Workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B5C87310-EF93-41A8-8A02-B9825023372B</gtr:id><gtr:impact>Participant, Wellcome Trust Drama Workshop, a forum for playwrights, producers and scientists to meet and discuss possible future collaborations

Established collaborative links</gtr:impact><gtr:outcomeId>LAamxFVKqCP</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>&quot;Parasite&quot; - visiting artist Deborah Robinson</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D267C917-8E96-4A31-A5FB-73EE64DE8776</gtr:id><gtr:impact>&amp;quot;Parasite&amp;quot;, joint project with Oliver Billker and Deborah Robinson, visiting artist. Exhibited in Cambridge, Heidelberg, Shanghai, and now installed at the Wellcome Genome Campus Conference Centre. Presents a new perspective on malaria elimination and the cyclical nature of the scientific challenges that malaria causes.

First exhibit Anglia Ruskin University 06/2013. Plan for future exhibits in 2014</gtr:impact><gtr:outcomeId>ov65g7jWAAn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.anglia.ac.uk/ruskin/en/home/microsites/ruskin_gallery/archive_201213/parasite.html</gtr:url><gtr:year>2013,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk to visiting schools</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>18C392F1-10C7-408E-89CB-171F76D2F2DF</gtr:id><gtr:impact>Over the past year I have given four talks to visiting school groups (30+ pupils) and school teachers (further development courses) about the impact of genome sequencing on malaria research, which stimulated much discussion about malaria in general and vaccine development in particular,

Feedback from teachers and students reported high level of interest in malaria after the talk</gtr:impact><gtr:outcomeId>Wa8uQRui4Sg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Society Summer Exhibit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D06B80CD-AB32-4168-99B0-23C35BF50D95</gtr:id><gtr:impact>Scientific steering group for the Sanger Institute exhibit at the 2013 Royal Society Summer Exhibit. Involved in planning and delivery; also volunteered for 2 days at the exhibit.

Dessimination of research to the lay public</gtr:impact><gtr:outcomeId>sXy3aw11bSr</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://sse.royalsociety.org/2013/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talks to undergraduate groups (Cambridge)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6107E35A-022D-4E08-AA5E-FE9715AAD4E5</gtr:id><gtr:impact>Two talks, each reaching 20-30 biology/medical undergraduate students.</gtr:impact><gtr:outcomeId>56d6b3df68d454.02386856</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Grant Panel Member, Wellcome Trust Engagement Fellowships</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5DEF74C7-BBCD-408A-A649-043B88542CF3</gtr:id><gtr:impact>Member of the WT panel awarding Public Engagement Fellowships

Four fellowships awarded over the past two years</gtr:impact><gtr:outcomeId>WF1rA36Jyze</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Blog on Malaria Challenge, an interactive website that explains malaria biology</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B82C8278-EA5B-4824-8085-7A0409EB6374</gtr:id><gtr:impact>I was recently involved in helping to create &amp;quot;Malaria Challenge&amp;quot;, an online multimedia tool (www.yourgenome.org) to explain malaria to high school students. In September 2012, I wrote a blog about the website, which was posted on BioMedCentral's Open Access in the Developing World website.

Retweets and Facebook recommends</gtr:impact><gtr:outcomeId>i8qBxx6X8Db</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Winner of: I'm A Scientist, Get Me Out Of Here</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>729D2BE4-3F73-4286-8D3E-F440202DF375</gtr:id><gtr:impact>I'm a Scientist, Get me out of here! was not just about attracting students to study and launch careers in science, but also to equip all involved with ways to think scientifically and help them become responsible citizens.

This was a rewarding experience for me as a scientist. We are totally enthused by the format as a tool for science communication, and we are now trying to spread the word about this fantastic science communication tool to as many schools as we can, by talking to teachers and spreading the word on the web. To help with this, we used the money that I won on I'm a Scientist, Get me out of here! to get loads of CDs burned with a web tool to help explain the malaria life-cycle (Malaria Challenge). We have mailed copies out to all the schools that participated in this and distribute the rest for free as widely as possible to schools all over the country.</gtr:impact><gtr:outcomeId>545b9e77463917.89798497</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://blog.wellcome.ac.uk/2011/06/16/any-questions-inside-i%E2%80%99m-a-scientist%E2%80%A6/</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Institutional Links Collaboration - Colombia</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>British Council</gtr:fundingOrg><gtr:fundingRef>172729106</gtr:fundingRef><gtr:id>8A32961B-D43F-4672-BB18-381DD28434EC</gtr:id><gtr:outcomeId>56d6b354607540.75254657</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>351298</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>MULTIVIVAX: Development of Effective Vaccines against Multiple Lifecycle Stages of Plasmodium vivax malaria</gtr:description><gtr:end>2022-12-02</gtr:end><gtr:fundingOrg>European Union</gtr:fundingOrg><gtr:id>D67918D9-0135-47B3-8776-97A28A9F8DFC</gtr:id><gtr:outcomeId>58c78c78433487.55835959</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>286605</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>NIH R01</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>R01-AI-091595-01A Primary Award; 557892 Sub-award</gtr:fundingRef><gtr:id>F9E06164-F29A-4A65-958C-E935E35BAAA5</gtr:id><gtr:outcomeId>HzKjBEtSQze</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Currently seeking funding for Phase I/IIa clinical trial</gtr:description><gtr:id>865D84B6-2F2C-40E8-8A01-4FA4BFE94891</gtr:id><gtr:impact>Based on our previous work using the AVEXIS system, extension of which has now been supported by the MRC, PfRH5 has been identified as a high priority blood stage vaccine target. We are carrying out pre-clinical optimisation, and seeking funding for a Phase I/IIa trial.</gtr:impact><gtr:outcomeId>iXuy2uMW6H7</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Rh5 based blood stage vaccine for Plasmodium falciparum</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Eukaryotic expression constructs for 52 full-length Plasmodium falciparum merozoite secreted proteins and 10 processed fragments of P. falciparum merozoite secreted proteins have been generated in the first two years of the award. Constructs have been deposited into not-for-profit plasmid repository, Addgene.</gtr:description><gtr:id>471EF508-1F79-400A-AD4A-526148213E1E</gtr:id><gtr:impact>Screens for erythrocyte binding and erythrocyte receptors ongoing</gtr:impact><gtr:outcomeId>XTFSCZc8shm</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Plasmodium falciparum merozoite protein expression constructs I</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.addgene.org/Gavin_Wright/</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A library of 30 plasmids for expression of Plasmodium vivax merozoite proteins; made freely available through Addgene.</gtr:description><gtr:id>E2B205A3-61B8-4DF6-BE36-94B133E45D61</gtr:id><gtr:impact>We have applied these tools to large-scale immunoepidemiology studies; others are using them to do the same.</gtr:impact><gtr:outcomeId>56d6b515993ba1.17554960</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Plasmodium vivax merozoite protein expression constructs</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>https://www.addgene.org/Julian_Rayner/</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9E6447F2-6905-4519-9D59-1A0B9363878E</gtr:id><gtr:title>Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0be031938faf037c8d52352b193fa9ee"><gtr:id>0be031938faf037c8d52352b193fa9ee</gtr:id><gtr:otherNames>Longley RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>5a9ad82ccd3370.32193039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E473AC13-5815-4B35-A93E-499BFA6256A1</gtr:id><gtr:title>Towards a comprehensive Plasmodium falciparum merozoite cell surface and secreted recombinant protein library.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98c598cc6c48a3ad981d3ca9d0d38f6c"><gtr:id>98c598cc6c48a3ad981d3ca9d0d38f6c</gtr:id><gtr:otherNames>Zenonos ZA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>54536373551c22.26551672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3773B160-BB24-4AD9-9F0E-ADC9C2C7402D</gtr:id><gtr:title>A Library of Plasmodium vivax Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein Interactions.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7382c412d1d22e15907b93de2e8001b6"><gtr:id>7382c412d1d22e15907b93de2e8001b6</gtr:id><gtr:otherNames>Hostetler JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>56d5b97fd56471.80433248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AB46949-BB6D-461D-8B23-B18213463C75</gtr:id><gtr:title>Identification of highly-protective combinations ofrecombinant proteins for vaccine development.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec3602db495ac58a04b65cce35643c0c"><gtr:id>ec3602db495ac58a04b65cce35643c0c</gtr:id><gtr:otherNames>Fran?a CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>5a2fd6c2b0d787.64816679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>149A95C6-4BFF-4F37-A1E1-29673391892C</gtr:id><gtr:title>An Antibody Screen of a Plasmodium vivax Antigen Library Identifies Novel Merozoite Proteins Associated with Clinical Protection.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec3602db495ac58a04b65cce35643c0c"><gtr:id>ec3602db495ac58a04b65cce35643c0c</gtr:id><gtr:otherNames>Fran?a CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>585d3e25500de8.76793910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74FDFD4A-58E9-48FC-97B2-566FC3DB6022</gtr:id><gtr:title>A library of functional recombinant cell-surface and secreted P. falciparum merozoite proteins.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e44dc5801845f58f7d9500ac50bb6478"><gtr:id>e44dc5801845f58f7d9500ac50bb6478</gtr:id><gtr:otherNames>Crosnier C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn><gtr:outcomeId>pm_14196_26_24043421</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07A05067-BCF7-4EA2-A5C8-7F0BED62FA49</gtr:id><gtr:title>RH5-Basigin interaction plays a major role in the host tropism of Plasmodium falciparum.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd5d1ea0da16beba4811129efd240a11"><gtr:id>fd5d1ea0da16beba4811129efd240a11</gtr:id><gtr:otherNames>Wanaguru M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_540e191e191358967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE8F011F-2C71-4D86-8B07-34C67497BE8B</gtr:id><gtr:title>Semaphorin-7A is an erythrocyte receptor for P. falciparum merozoite-specific TRAP homolog, MTRAP.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/780bffa19e666abb6619ce7035766e5a"><gtr:id>780bffa19e666abb6619ce7035766e5a</gtr:id><gtr:otherNames>Bartholdson SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>afS8hBsGAt8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DAB733E-06FD-445B-B25A-ED289D3CB434</gtr:id><gtr:title>Biochemical analysis of the Plasmodium falciparum erythrocyte-binding antigen-175 (EBA175)-glycophorin-A interaction: implications for vaccine design.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd5d1ea0da16beba4811129efd240a11"><gtr:id>fd5d1ea0da16beba4811129efd240a11</gtr:id><gtr:otherNames>Wanaguru M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_14196_26_24043627</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51864E63-77ED-4C48-BA73-41C7576A144A</gtr:id><gtr:title>Plasmodium falciparum erythrocyte invasion: combining function with immune evasion.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f699abf8a525406ccbe9a57c361f9360"><gtr:id>f699abf8a525406ccbe9a57c361f9360</gtr:id><gtr:otherNames>Wright GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_540e191e191410468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B00D5335-7621-48BE-95FA-FAEE6736F7D8</gtr:id><gtr:title>New antigens for a multicomponent blood-stage malaria vaccine.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/522e3401574cd4c13fb6eea59f5f9167"><gtr:id>522e3401574cd4c13fb6eea59f5f9167</gtr:id><gtr:otherNames>Osier FH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>545b61566c5c70.38297570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>853D949F-CA05-47F0-AF9F-419EE7703E26</gtr:id><gtr:title>Synergistic malaria vaccine combinations identified by systematic antigen screening.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c05920d9c0d0723b5621a4d6656c7cb"><gtr:id>5c05920d9c0d0723b5621a4d6656c7cb</gtr:id><gtr:otherNames>Bustamante LY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5a9ad7ebc0a400.89902832</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J002283/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>